THE INCIDENCE, MORTALITY, AND SURVIVAL OF MALIGNANT GASTRIC CANCER IN THE UNITED STATES: A SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) 2000-2023 DATABASE ANALYSIS
Author(s)
Filip Stanicic, PhD (c), Dimitrije Grbic, PhD (c), Vlad Zah, PhD.
Health Economist, ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
Health Economist, ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
OBJECTIVES: Analyzing the disease burden in US population of gastric cancer (GC) diagnosis using updated Surveillance, Epidemiology, and End Results (SEER) data (April 2026).
METHODS: Data from 21 cancer registries (2000-2023) was analyzed with SEER*Stat. GC cases were identified using primary cancer site codes. Only malignant cases were included. Outcome measures were crude incidence and mortality rates (reported per 100,000 population) and 1-year and 5-year survival rates. Incidence and mortality trends were reported as annual percent change (APC), calculated using the weighted least squares method.
RESULTS: There were 295,476 cases in the final sample. Cardia GC was the most common subtype (24.8%). Patients were predominantly males (59.4%), elderly (61.0%), Non-Hispanic Whites (53.7%), metropolitan county residents (89.5%), and had $65,000-$90,000 annual household income (AHI) (49.3%). GC incidence was 8.642 in the US. The highest rates across categories were 2.143 for cardia GC, 40.497 for elderly, 10.399 for males, 11.114 for Non-Hispanic Asians/Pacific Islanders, 8.653 for metropolitan residents, and 9.706 for <$40,000 AHI. The greatest increasing incidence trend was observed for stomach body GC (APC 3.142, p<0.050) and decreasing trend for antrum GC (APC -0.833, p<0.050). GC mortality was 6.247 in the US. Across categories, the highest rates were reported for cardia GC (1.697), males (7.790), Non-Hispanic Asian/Pacific Islander (7.369), non-metropolitan residents (6.669), and <$40,000 AHI (7.777). Mortality trends either were stable or increasing across subtypes, with the greatest increase for stomach body GC (APC 2.828, p<0.050). The highest survival had greater curvature GC (1-year 69.2%, 5-year 45.0%). The lowest rates were reported for overlapping lesions GC (1-year 49.6%) and cardia GC (5-year 22.1%).
CONCLUSIONS: Based on the results of this study, real-world burden of GC is high in the US. Increasing mortality trends between 2000-2023 with low survival rates in recent years point out an urgent need for new effective treatments.
METHODS: Data from 21 cancer registries (2000-2023) was analyzed with SEER*Stat. GC cases were identified using primary cancer site codes. Only malignant cases were included. Outcome measures were crude incidence and mortality rates (reported per 100,000 population) and 1-year and 5-year survival rates. Incidence and mortality trends were reported as annual percent change (APC), calculated using the weighted least squares method.
RESULTS: There were 295,476 cases in the final sample. Cardia GC was the most common subtype (24.8%). Patients were predominantly males (59.4%), elderly (61.0%), Non-Hispanic Whites (53.7%), metropolitan county residents (89.5%), and had $65,000-$90,000 annual household income (AHI) (49.3%). GC incidence was 8.642 in the US. The highest rates across categories were 2.143 for cardia GC, 40.497 for elderly, 10.399 for males, 11.114 for Non-Hispanic Asians/Pacific Islanders, 8.653 for metropolitan residents, and 9.706 for <$40,000 AHI. The greatest increasing incidence trend was observed for stomach body GC (APC 3.142, p<0.050) and decreasing trend for antrum GC (APC -0.833, p<0.050). GC mortality was 6.247 in the US. Across categories, the highest rates were reported for cardia GC (1.697), males (7.790), Non-Hispanic Asian/Pacific Islander (7.369), non-metropolitan residents (6.669), and <$40,000 AHI (7.777). Mortality trends either were stable or increasing across subtypes, with the greatest increase for stomach body GC (APC 2.828, p<0.050). The highest survival had greater curvature GC (1-year 69.2%, 5-year 45.0%). The lowest rates were reported for overlapping lesions GC (1-year 49.6%) and cardia GC (5-year 22.1%).
CONCLUSIONS: Based on the results of this study, real-world burden of GC is high in the US. Increasing mortality trends between 2000-2023 with low survival rates in recent years point out an urgent need for new effective treatments.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EPH238
Topic
Clinical Outcomes, Epidemiology & Public Health, Real World Data & Information Systems
Disease
Gastrointestinal Disorders, No Additional Disease & Conditions/Specialized Treatment Areas, Oncology